CTE Sessions at EANM’16

EANM’16 – Mini Course II

October 16, 2016, 15:45 – 16:45
Updates in Radiopharmaceuticals for PET

Chairpersons: S. Rep (Ljubljana), C. Abreu (London)


Speakers:
extended
abstract
P. Kolenc Peitl (Ljubljana):
New PET Tracers and Oncology
E. Demirci (Istanbul):
New PET Tracers and Neurology


Educational objectives:

  1. To get acquainted with new tracers in PET/CT investigations
  2. To get acquainted with the clinical use of the new PET/CT tracers
  3. To get acquainted with the advantages and disadvantages of the new PET/CT tracers
  4. To get acquainted with production and tracers synthesis


Summary:

The advantages of PET/CT technology will lead to the introduction of new PET tracers for established nuclear medicine imaging indications. Specific markers such as amyloid ligands will lead to applications of PET/CT to neurodegenerative diseases. The first step in the diagnosis of prostate cancer is often an anomalous prostate specific antigen (PSA) value. Diagnosis of prostate cancer is also possible with radiolabeled amino acids; 11C-acetat, 18F and 11C-cholin. For diagnosis in somatostatin-receptor positive neuroendocrine tumors can be used 68Ga –DOTATATE or 18F-FDOPA. Through lectures in this session, the audience will note with new radiopharmaceuticals that are used besides the 18F FDG in oncology and neurology. The audience will inform about clinical use, production and tracers synthesis, advantages and disadvantages


Key Words:

PET/CT, oncology, neurology, amyloid ligands, amino acids, neuroendocrine tumors

Back to top